| Company | Historical Revenue (2020, USD Billion) | Current Annual Revenue (2024, USD Billion) | Year |
|---|---|---|---|
| Medtronic plc | 27.5 | 32.4 | 2024 |
| Abbott Laboratories | 34.6 | 41.9 | 2024 |
| Boston Scientific Corporation | 9.9 | 14.2 | 2024 |
| Becton, Dickinson and Company | 17.1 | 20.0 | 2024 |
| Edwards Lifesciences | 4.4 | 6.2 | 2024 |
| Stryker Corporation | 14.4 | 20.5 | 2024 |
| B. Braun Melsungen AG | 8.2 | 9.5 | 2024 |
| Terumo Corporation | 6.2 | 7.8 | 2024 |
Medtronic plc is a global leader in medical technology, providing innovative solutions in cardiovascular, diabetes, neuroscience, and surgical care. The company focuses on advancing minimally invasive treatments and life-saving devices that improve patient outcomes across over 150 countries. Medtronic continues to strengthen its position through groundbreaking technologies like pulsed field ablation (PFA) and next-generation insulin delivery systems.
MiniMed™ 780G insulin pump integrated with Simplera™ CGM for diabetes management.
PulseSelect™ pulsed field ablation (PFA) system for cardiac rhythm management.
Core offerings in pacemakers, spinal implants, and neuromodulation devices.
Expansion of next-generation cardiac ablation systems with global rollout of PFA technology.
Investment in artificial intelligence and digital health integration across therapeutic areas.
Streamlined operations to enhance profitability through cost optimization and focused R&D.
Provides healthcare solutions that reach over 70 million patients annually worldwide.
Drives innovations that redefine standards of care in cardiovascular and diabetes treatment.
Supports sustainable healthcare access programs in emerging economies.
Pricing pressure in key global markets and healthcare reimbursement constraints.
Supply chain disruptions impacting device production and distribution.
Intense competition in electrophysiology and diabetes care segments.
FDA approval of the Simplera™ CGM for integration with MiniMed™ 780G system.
Global launch of the PulseSelect™ PFA system for safer cardiac ablation.
Continued investment in AI-driven surgical assistance technologies.
Abbott Laboratories is a diversified healthcare company focusing on diagnostics, medical devices, nutrition, and branded generics. Its innovative portfolio serves millions worldwide, driven by advancements in diabetes care, cardiovascular devices, and diagnostics. The company’s agile response to healthcare needs has positioned it as a key player in global medtech innovation.
FreeStyle Libre® continuous glucose monitoring systems.
MitraClip™ device for mitral valve repair and AVEIR™ leadless pacemaker.
Alinity™ diagnostic testing systems used across clinical laboratories globally.
Focus on continuous innovation in diabetes and cardiovascular care.
Expansion into remote monitoring and connected health technologies.
Strategic partnerships to enhance global distribution and market penetration.
FreeStyle Libre® devices are used by over 5 million people globally.
Strong presence in over 160 countries with a focus on improving chronic disease management.
Pioneer in accessible glucose monitoring solutions, empowering patient-driven care.
Competitive pressure from emerging CGM manufacturers and pricing constraints.
Regulatory challenges in expanding device approvals across multiple markets.
Currency fluctuations affecting international revenue streams.
Launch of FreeStyle Libre 3 system with smartphone-based glucose monitoring.
Introduction of AVEIR™ DR dual-chamber leadless pacemaker for heart rhythm management.
Expansion of Alinity™ diagnostic platforms to enhance global lab efficiency.
Boston Scientific is a leading developer of medical solutions in cardiology, endoscopy, urology, and neuromodulation. The company’s focus on innovation and clinical outcomes has made it a trusted partner in improving patient health worldwide. With an expanding digital ecosystem and robust R&D pipeline, Boston Scientific continues to drive minimally invasive advancements.
WATCHMAN™ FLX left atrial appendage closure device.
POLARx™ cryoablation system for atrial fibrillation.
SPECTRA WAVEWRITER™ spinal cord stimulator for pain management.
Diversification through acquisitions in structural heart and electrophysiology segments.
Strengthening global market presence with localized manufacturing and supply chains.
Integration of AI and real-world data to enhance product effectiveness.
Devices used in over 120 countries improving cardiovascular and neurological care.
Leading role in reducing stroke risk and improving arrhythmia treatments.
Major contributor to advancing minimally invasive surgical techniques.
Integration complexity following frequent acquisitions.
Cost management amid raw material inflation and regulatory scrutiny.
Rising competition in cardiac rhythm management from new entrants.
Expansion of the POLARx™ Cryoablation System across global markets.
Launch of the Farapulse™ PFA System after regulatory clearance.
Strategic acquisitions in electrophysiology and heart therapy divisions.
BD is a global leader in medical devices, laboratory systems, and reagents. The company specializes in advancing diagnostics, biosciences, and drug delivery systems to improve clinical safety and healthcare outcomes. BD’s commitment to innovation has made it a trusted partner in global healthcare infrastructure.
BD Vacutainer® blood collection systems.
BD MAX™ molecular diagnostic platform.
BD Alaris™ infusion pumps and drug delivery systems.
Strengthening infection prevention and diagnostic testing portfolio.
Expanding manufacturing capacity to ensure supply chain resilience.
Strategic collaborations to accelerate digital transformation in healthcare.
Operates in over 190 countries with a strong presence in hospitals and labs worldwide.
Plays a vital role in supporting vaccination programs and blood testing safety.
Leader in diagnostic innovation and clinical efficiency tools.
Regulatory challenges regarding infusion pump updates and compliance.
Increased costs from supply chain disruptions and inflation.
Competition in diagnostics and testing products post-pandemic.
Launch of BD MiniDraw™ capillary blood collection technology.
Expansion of Alaris™ infusion pump system in the U.S. market.
New investments in automated sample processing and point-of-care testing.
Edwards Lifesciences is a pioneer in heart valve therapies and critical care monitoring. The company revolutionized structural heart disease treatment through its transcatheter aortic valve replacement (TAVR) technology. Edwards remains focused on patient-centered innovations that improve survival and recovery rates globally.
SAPIEN™ transcatheter heart valve series.
HemoSphere™ advanced hemodynamic monitoring platform.
KONECT RESILIA™ aortic valved conduit for cardiovascular surgery.
Continuous R&D investment to expand TAVR and mitral/tricuspid valve therapies.
Global expansion into emerging markets with growing cardiovascular disease prevalence.
Integration of data-driven monitoring tools to support personalized care.
Over 1 million patients treated with Edwards’ TAVR systems worldwide.
Significant reduction in open-heart surgeries through minimally invasive procedures.
Contributions to early diagnosis and improved cardiac recovery outcomes.
Intense competition from Medtronic and Abbott in TAVR and valve repair.
Pricing and reimbursement challenges in developing countries.
Regulatory delays impacting new product rollouts.
Expansion of SAPIEN 3 Ultra RESILIA valve in global markets.
Advancements in smart hemodynamic monitoring technology.
Initiation of new clinical trials for next-gen transcatheter mitral solutions.
Stryker Corporation is one of the world’s leading medical technology companies specializing in orthopedic implants, surgical equipment, and neurotechnology. The company’s mission revolves around improving patient outcomes through innovative surgical solutions and robotic-assisted systems. With a strong focus on digital integration and surgical precision, Stryker has maintained consistent global leadership in orthopedics and medical devices.
Mako™ robotic-arm assisted surgery system for joint replacements.
Neptune™ waste management system for operating rooms.
Tritanium® 3D-printed spinal implants and orthopedic devices.
Expansion of robotic-assisted surgery and AI-driven surgical planning tools.
Strengthening presence in emerging markets through acquisitions and localized production.
Increased R&D spending in neurotechnology and minimally invasive surgery innovations.
More than 1.5 million robotic-assisted surgeries performed globally using Mako™ systems.
Operates in over 75 countries with a workforce exceeding 50,000 employees.
Plays a major role in advancing orthopedics, improving precision and recovery outcomes.
Rising raw material and manufacturing costs impacting margins.
Competitive pressure in the orthopedic robotics segment from Zimmer Biomet and Smith & Nephew.
Regulatory hurdles for new orthopedic implant approvals in various regions.
Launch of the next-generation Mako™ Total Knee 2.0 platform in 2024.
Acquired Vocera Communications to enhance connectivity in hospitals.
Expansion of digital surgery platforms and data analytics capabilities.
B. Braun Melsungen AG is a German medical and pharmaceutical device company known for its excellence in infusion therapy, pain management, and surgical systems. The company emphasizes patient safety, innovation, and sustainable healthcare delivery. With operations in over 60 countries, B. Braun’s solutions are widely integrated into hospitals and clinical settings.
Infusomat® Space and Perfusor® Space infusion pump systems.
Aesculap® surgical instruments and implants for orthopedic and neurosurgery.
Dialysis machines and accessories under the Dialog+ brand.
Enhancing automation and smart infusion systems for safer medication delivery.
Investing in green manufacturing and circular economy initiatives.
Collaborating with hospitals to develop digitalized operating rooms.
Serves healthcare institutions in over 180 countries with 60,000+ employees.
Supplies critical care products supporting millions of surgeries annually.
Promotes sustainable healthcare practices through eco-friendly manufacturing.
Supply chain complexities and inflationary pressures on raw materials.
Need for continuous compliance with stringent European and FDA regulations.
Growing competition in the infusion and dialysis markets.
Introduced an AI-based infusion monitoring system to reduce clinical errors.
Expanded its Aesculap® portfolio with titanium orthopedic implants.
Launched new environmentally friendly packaging for infusion products.
Terumo Corporation, based in Japan, is a leading global medical technology company specializing in cardiovascular systems, blood management, and general hospital products. It focuses on developing advanced devices for interventional procedures and diagnostics, driving patient-centered innovation across 160 countries.
Terumo® Guidewires and catheters for cardiovascular and neurovascular interventions.
Blood component collection systems and transfusion technologies.
Ultimaster™ drug-eluting coronary stent system.
Expanding interventional oncology and cardiovascular portfolios.
Strengthening global R&D and manufacturing through regional hubs.
Investment in digital and AI-based interventional imaging solutions.
Serves millions of cardiovascular patients annually with advanced medical devices.
Promotes minimally invasive procedures through cutting-edge catheter and stent innovations.
Plays a key role in advancing blood safety and transfusion systems worldwide.
Competitive pressure from Medtronic and Boston Scientific in cardiology.
Regulatory delays in new product approvals across regional markets.
Managing operational costs amid fluctuating global supply chain conditions.
Launched the Ultimaster™ Nagomi drug-eluting stent for complex coronary lesions.
Expanded its digital healthcare segment with AI-assisted vascular imaging tools.
Established a new R&D center in Japan focused on interventional oncology solutions.
The global catheters market size is calculated at US$ 37.62 in 2024, grew to US$ 40.3 billion in 2025, and is projected to reach around US$ 74.64 billion by 2034. The market is expanding at a CAGR of 7.12% between 2025 and 2034.
Demand for Minimally Invasive Surgeries: By providing patients with less intrusive options than standard operations, minimally invasive procedures have completely changed the medical field. These operations use cutting-edge technology to operate through tiny incisions, which leads to a speedier recovery and fewer problems. Patients looking for cutting-edge medical care are increasingly using these procedures.
For instance,
Concept creation, material selection, design, and prototyping are all part of catheter research and development. To guarantee safety and effectiveness, these steps are followed by thorough testing and validation. Before the final product is prepared for use, it must undergo sterile packing and sterilisation to satisfy stringent medical and regulatory requirements.
Key Companies: Medtronic, Boston Scientific, Teleflex, and Johnson & Johnson
A complicated procedure is used to distribute catheters to pharmacies and hospitals, guaranteeing that these medical supplies are easily accessible for patient care. This covers purchasing, storing, and dispensing; these tasks are frequently overseen by the hospital pharmacy or an authorised distributor of medical supplies.
Key Companies: Medtronic, Boston Scientific Corporation, Teleflex Incorporated, and B. Braun SE, along with distributors like McKesson Corporation.
Education, good cleanliness, and handling any problems are the main goals of patient support and services for catheter care. The goal of these services is to enable patients to properly care for their catheters and avoid infections. This covers how to properly insert and remove a catheter (if necessary), maintain a drainage bag, maintain good perineal cleanliness, and spot infection or other problems.
Key Companies: Medtronic, Teleflex, Coloplast, Convatec, and Cardinal Health
In September 2024, we are pleased to announce that EMBOGUARD has joined our family of CERENOVUS Stroke Solutions in Europe, stated CERENOVUS Worldwide President Mark Dickinson. This addition to our technology portfolio strengthens our resolve to alter the course of stroke by giving doctors a cutting-edge and all-inclusive toolkit to treat their patients.
Become a valued research partner with us, please feel free to contact us at sales@towardshealthcare.com
